Cargando…

Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis

Pulmonary hypertension (PH) complicating chronic obstructive pulmonary disease (COPD-PH) and interstitial lung disease (ILD-PH) (World Health Organization [WHO] Group III PH) increases medical costs and reduces survival. Despite limited data, many clinicians are using pulmonary arterial hypertension...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prins, Kurt W., Duval, Sue, Markowitz, Jeremy, Pritzker, Marc, Thenappan, Thenappan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448533/ https://www.ncbi.nlm.nih.gov/pubmed/28680574 http://dx.doi.org/10.1086/690017

Ejemplares similares

Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis
por: Kalra, Rajat, et al.
Publicado: (2020)

Carvedilol for Treatment of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Thenappan, Thenappan, et al.
Publicado: (2021)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again
por: Prins, Kurt W., et al.
Publicado: (2018)

Clinical Determinants and Prognostic Implications of Right Ventricular Dysfunction in Pulmonary Hypertension Caused by Chronic Lung Disease
por: Prins, Kurt W., et al.
Publicado: (2019)

Sex differences in right ventricular function between Groups 1 and 3 pulmonary hypertension
por: Kazmirczak, Felipe, et al.
Publicado: (2023)

Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2020)

Effect of Chronic Digoxin Use on Mortality and Heart Failure Hospitalization in Pulmonary Arterial Hypertension
por: Chang, Kevin Y., et al.
Publicado: (2023)

With No Lysine Kinase 1 Promotes Metabolic Derangements and RV Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2021)

Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension
por: Prins, Kurt W., et al.
Publicado: (2020)

Hemodynamic Characteristics and Outcomes of Pulmonary Hypertension in Patients Undergoing Tricuspid Valve Repair or Replacement
por: Vijayaraghavan, Mahima, et al.
Publicado: (2020)

Pulmonary hypertension in chronic kidney disease: a hemodynamic characterization
por: Thenappan, Thenappan
Publicado: (2017)

Colchicine Depolymerizes Microtubules, Increases Junctophilin‐2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension
por: Prins, Kurt W., et al.
Publicado: (2017)

Pulmonary Arterial Hypertension and Sex in the Right Ventricle: It Is an Interesting Picture!
por: Thenappan, Thenappan, et al.
Publicado: (2020)

Intermittent Fasting Enhances Right Ventricular Function in Preclinical Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2021)

Late-onset pulmonary arterial hypertension in repaired D-transposition of great arteries: an uncommon complication
por: Baskaran, Janani, et al.
Publicado: (2017)

Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
por: Chang, Kevin Y., et al.
Publicado: (2022)

Ingenuity pathway analysis of the human cardiac cell Atlas identifies differences between right and left ventricular cardiomyocytes
por: Prisco, Sasha Z., et al.
Publicado: (2022)

Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
por: Thenappan, Thenappan, et al.
Publicado: (2020)

Incidence and Risk Factors of Pulmonary Hypertension After Venous Thromboembolism: An Analysis of a Large Health Care Database
por: Lutsey, Pamela L., et al.
Publicado: (2022)

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
por: Chaturvedi, Abhishek, et al.
Publicado: (2020)

The WHO classification of pulmonary hypertension: A case-based imaging compendium
por: Ryan, John J., et al.
Publicado: (2012)

Excess Protein O-GlcNAcylation Links Metabolic Derangements to Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2020)

Pulmonary tumor thrombotic microangiopathy: Exploration into current diagnostic aids and therapeutics
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)

Heart Failure Hospitalization Trends During the Early Phase of the COVID 19 Pandemic
por: Fraser, Meg, et al.
Publicado: (2020)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Ketone bodies in right ventricular failure: A unique therapeutic opportunity
por: Blake, Madelyn, et al.
Publicado: (2023)

Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry
por: Fakhri, Shoaib, et al.
Publicado: (2020)

Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study
por: Waxman, Aaron, et al.
Publicado: (2023)

Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
por: Steele, Peter, et al.
Publicado: (2010)

Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps
por: Kanwar, Manreet K., et al.
Publicado: (2021)

Symptom phenotypes in pulmonary arterial hypertension: The PAH “symptome”
por: Matura, Lea Ann, et al.
Publicado: (2022)

Resistance over compliance describes right ventricular afterload better than resistance-compliance time: a friendly amendment
por: Thenappan, Thenappan, et al.
Publicado: (2017)

Health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR)
por: Minhas, Jasleen, et al.
Publicado: (2021)

Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application
por: Al-Hilal, Taslim A., et al.
Publicado: (2020)

Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry
por: DuBrock, Hilary M., et al.
Publicado: (2021)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Hypotension on cardiopulmonary stress test predicts 90 day mortality after LVAD implantation in INTERMACS 3–6 patients
por: Maharaj, Valmiki, et al.
Publicado: (2022)

Robotic-assisted vs. open radical prostatectomy: an update to the never-ending debate
por: Chandrasekar, Thenappan, et al.
Publicado: (2018)

External assessment of the EUROMACS right-sided heart failure risk score
por: Shah, Hirak, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ji1969vqb8comhsitptsuqpnba